Minocycline Treatment in Acute Hemorrhagic Stroke
Information source: Wolfson Medical Center
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Poor Performance Status
Phase: N/A
Status: Not yet recruiting
Sponsored by: Wolfson Medical Center Official(s) and/or principal investigator(s):
Yair Lampl, MD, Principal Investigator, Affiliation: Edith Wolfson Medical Center
Summary
The investigators will perform a double blind controlled study to investigate the efficacy
of oral administration of 200 mg minocycline, on the neurological and functional outcome
after acute hemorrhagic stroke and the effect on blood brain barrier permeability.
Clinical Details
Official title: Minocycline Treatment in Acute Hemorrhagic Stroke for Evaluation of Treatment Efficacy and Blood Brain Barrier Permeability
Study design: Observational Model: Cohort, Time Perspective: Prospective
Detailed description:
Minocycline, a semisynthetic second generation derivative of tetracycline, was shown to have
a clear beneficial neuroprotective effect in animal models of multiple sclerosis,
Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Animal models
provide promising evidence of minocycline's ability to improve outcomes in an animal stroke
model.
In light of these findings, we will perform a double blind controlled study to investigate
the efficacy of oral administration of 200 mg minocycline, on the neurological and
functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier
permeability.
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with acute hemorrhagic stroke
1. age > 18
2. NIHSS score > 5
3. onset of stroke 6 to 24 hours prior to beginning of treatment. Patients, who
arrived within 0 to 6 hours post stroke, were treated with other medications
according to the best accepted medical treatment guidelines.
Exclusion Criteria:
1. Evidence of other disease of the central nervous system, including brain tumor,
demyelinating disease, inflammatory disease of the central nervous system, craniotomy
in the past, severe brain injuries and benign intracranial hypertension
2. pre-existing neurological disability
3. known allergic response to tetracyclines
4. acute or chronic renal failure
5. pre-existing infectious disease requiring antibiotic therapy
6. swallowing difficulties
Locations and Contacts
Edith Wolfson Medical Center, Holon 58100, Israel; Not yet recruiting
Yair Lampl, MD, Phone: 972-3-5028512, Ext: 8512, Email: y_lampl@hotmail.com
Yair Lampl, MD, Principal Investigator
Additional Information
Starting date: July 2011
Last updated: July 5, 2011
|
